Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/139547| Title: | Drug design and optimisation at the IL-1 Receptor-Associated Kinase (IRAK) receptor |
| Authors: | Decelis, Justine Shoemake, Claire |
| Keywords: | Interleukin-1 Receptor-Associated Kinases Drugs -- Design Pharmaceutical chemistry Pharmacokinetics Protein kinases -- Inhibitors |
| Issue Date: | 2025 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Decelis, J., & Shoemake, C. (2025). Drug design and optimisation at the IL-1 Receptor-Associated Kinase (IRAK) receptor. Poster session presented at the 83rd FIP World Congress of Pharmacy and Pharmaceutical Sciences, Copenhagen. |
| Abstract: | Introduction: IRAK4 activation is crucial in autoimmune diseases and tumour development. CA
4948 (Emavusertib) is actively undergoing
phase 1/ 2 clinical trials as stand alone therapy or in combination with other agents. It has been found to be the most
effective IRAK4 inhibitor exhibiting favourable selectivity over other kinases, cellular activity, efficacy, pharmacokinetics and
safety while also regressing tumour growth without any overt toxicity. Due to the inadequate pharmacological treatment
used for both pathologies, there is an ongoing need for new and effective IRAK4 receptor inhibitors. Aims: The aim of this study was to use the scaffolds of experimental inhibitors CA 4948 and FJ 9 to design novel molecules with the propensity to antagonise the IRAK 4 receptor using Virtual Screening and de Novo design. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/139547 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Drug design and optimisation at the IL 1 Receptor Associated Kinase IRAK receptor 2025.pdf | 448.78 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.